drugset / Trial / NCT00864396

Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

NCT00864396

Phase 1 Completed 59 enrolled University of California, Davis
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Timeline

Start
2005-07
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg